Analyst Price Targets — SRZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2026 10:12 am | — | H.C. Wainwright | $44.00 | $34.13 | TheFly | Surrozen price target raised to $44 from $36 at H.C. Wainwright |
| February 19, 2026 11:13 am | — | Cantor Fitzgerald | $40.00 | $25.09 | TheFly | Surrozen initiated with an Overweight at Cantor Fitzgerald |
| January 30, 2025 11:04 am | Matthew Caufield | H.C. Wainwright | $32.00 | $11.25 | TheFly | Surrozen initiated with a Buy at H.C. Wainwright |
| January 3, 2025 11:15 am | Yatin Suneja | Guggenheim | $45.00 | $17.45 | TheFly | Surrozen upgraded to Buy from Neutral at Guggenheim |
Latest News for SRZN
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug…
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences.
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc.…
Surrozen NASDAQ: SRZN Chief Executive Officer Craig Parker outlined the company's rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright's 6th Annual Ophthalmology Investor Conference, emphasizing the company's focus on Frizzled-4 signaling, anti-VEGF activity and, in one preclinical program, IL-6 inhibition.
Surrozen to Present at Upcoming Healthcare Investor Conference: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRZN.
U.S. House Trading
No House trades found for SRZN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.